

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1459

Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/656,360 09/05/2003		Mitsunori Ono	09808-017002	7835	
26161	7590 03/16/2005		EXAMINER		
FISH & RICHARDSON PC 225 FRANKLIN ST			BALASUBRAMANIAN, VENKATARAMAN		
BOSTON, MA 02110			ART UNIT	PAPER NUMBER	
			1624		

DATE MAILED: 03/16/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

					_			
		Applicati	on No.	Applicant(s)				
Office Action Summary		10/656,3	60	ONO ET AL.				
		Examine	r	Art Unit				
	•	Venkatar	aman Balasubramanian	1624				
Period fo	The MAILING DATE of this commun or Reply	ication appears on th	e cover sheet with the	correspondence addres	SS			
THE - Exte after - If the - If NC - Failt Any	ORTENED STATUTORY PERIOD F MAILING DATE OF THIS COMMUNI nsions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comm p period for reply specified above is less than thirty (3 p period for reply is specified above, the maximum st ure to reply within the set or extended period for reply reply received by the Office later than three months a ed patent term adjustment. See 37 CFR 1.704(b).	CATION. of 37 CFR 1.136(a). In no expunication. 0) days, a reply within the statutory period will apply and will, by statute, cause the apply.	rent, however, may a reply be ti tutory minimum of thirty (30) da rill expire SIX (6) MONTHS from plication to become ABANDONE	mely filed ys will be considered timely. In the mailing date of this commu	<i>u</i> nication.			
Status								
1)⊠	Responsive to communication(s) file	ed on 20 December 2	2004.					
•	This action is FINAL . 2b)⊠ This action is non-final.							
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims							
5)⊠ 6)⊠ 7)□	Claim(s) 47 and 49-100 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. Claim(s) 55-100 is/are allowed. Claim(s) 47 and 49-54 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or election requirement.							
Applicat	ion Papers							
10)	The specification is objected to by the The drawing(s) filed on is/are: Applicant may not request that any objected to specific the property of the country of the co	a) accepted or b ction to the drawing(s) the correction is requi	be held in abeyance. Se red if the drawing(s) is ob	e 37 CFR 1.85(a). pjected to. See 37 CFR 1	` '			
Priority (under 35 U.S.C. § 119							
12)□ a)	Acknowledgment is made of a claim All b) Some * c) None of: 1. Certified copies of the priority 2. Certified copies of the priority 3. Copies of the certified copies application from the Internation See the attached detailed Office action	documents have been documents have been of the priority documnal Bureau (PCT Ru	en received. en received in Applicat ents have been receiv le 17.2(a)).	ion No ed in this National Sta	ge			
	e of References Cited (PTO-892)		4) Interview Summary					
3) 🔲 Infor	e of Draftsperson's Patent Drawing Review (P mation Disclosure Statement(s) (PTO-1449 or r No(s)/Mail Date		Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate Patent Application (PTO-152	2)			

Art Unit: 1624

DETAILED ACTION

Applicants' response, which included cancellation of claim 48, amendment to claim 47 and addition of new claims 49-100, filed on 12/20/2004, is made of record.

Claims 47 and 49-100 are now pending.

Specification

Specification under cross references to related applications need to amended to indicate the applications 10/006,624 and 09/594,362 are now US Patents 6,680,315 and 6,384,032 respectively.

In view of applicants' amendment to claim 47, the 112 first paragraph rejection made in the previous office action has been obviated.

However the following rejections apply.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Application/Control Number: 10/656,360

Art Unit: 1624

Claims 47 and 49-54 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 26-34 of U.S. Patent No. 6,384,032. Although the conflicting claims are not identical, they are not patentably distinct from each other because the same method of uses claimed in the instant claims are also generically claimed in the claims 26-34 of US 6,384,034.

. Instant method of use claims 47 and 49-54 are rejected over mode of action claims 26-34 of US 6,384,034, as mode of action relates to treatment of the diseases. In this regard applicants attention to drawn to the court decision, wherein the court held that double Patenting applies between a mode of action and the treatment of disease if one of ordinary skill in the art would know of the connection between the two. See Lilly vs. Barr, 58 USPQ2d 1869, at 1879.

Allowable Subject Matter

Claims 55-100 would be allowable as prior art search in the relevant art area did not teach or suggest the pharmaceutical composition embraced in the claims 55-100.

Conclusion

Any inquiry concerning this communication from the examiner should be addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571) 272-0662. The examiner can normally be reached on Monday through Thursday from 8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is Mukund Shah whose telephone number is (571) 272-0674. If Applicants are unable to reach Mukund Shah within 24-hour period, they may contact James O. Wilson, Acting-SPE of art unit 1624 at 571-272-0661. The fax phone number for the organization

Application/Control Number: 10/656,360

Art Unit: 1624

Page 4

where this application or proceeding is assigned (703) 872-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be

directed to the receptionist whose telephone number is (571) 272-1600.

Venhataramen Balasubamanan Venkataraman Balasubramanian

3/12/2005